VRAX on Nasdaq
Virax Biolabs Group Ltd
Our legal name is Virax Biolabs Group Limited, and our commercial name is “Virax Biolabs.” We are an exempted company with limited liability incorporated under the laws of the Cayman Islands.4 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerVRAX on Nasdaq2
- IndustryIn Vitro & In Vivo Diagnostic Substances2
- HeadquartersGeorge Town, Cayman Islands2
- Incorporated inCayman Islands3
- Business addressBiocity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire, X0 Ml1 5Uh3
- Filer categoryNon-accelerated filer, Emerging growth company3
- Legal formCorporation2
- LEI25490017YHIJPOXAXI932
- StatusActive2
- LEI statusIssued and current2
- Registered addressC/O Ogier Global (Cayman) Limited, KY1-9009 George Town, Cayman Islands2
- Registered withGeneral Registry, OC-3804402
See how the biggest companies compare on our leaderboards
Our legal name is Virax Biolabs Group Limited, and our commercial name is “Virax Biolabs.” We are an exempted company with limited liability incorporated under the laws of the Cayman Islands. Our principal executive offices are located at BioCity Glasgow, Bo’Ness Road, Newhouse, Lanarkshire, ML1 5UH. Our telephone number is +44 020 7788 7414.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.8
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Revenue | $12.4K | $6.3K | $156.4K |
| Cost of revenue | $4.7K | $59.4K | $105.8K |
| Gross profit (loss) | $7.7K | -$53.1K | $50.6K |
| General and administrative | $2.7M | $4.0M | $4.6M |
| Research & development | $3.7M | $2.0M | $1.6M |
| Impairment of intangible asset | $0 | $0 | $390.4K |
| Total operating expenses | $6.4M | $6.0M | $6.6M |
| Operating loss | -$6.4M | -$6.1M | -$6.5M |
| Interest expense, net | -$61.8K | -$58.2K | -$26.9K |
| Other income (expense), net | $33 | $17.2K | -$215.8K |
| Foreign currency gain (loss), net | $529.0K | -$86.1K | $29.2K |
| Total other income (expense), net | $467.3K | -$127.1K | -$213.4K |
| Loss before income taxes | -$5.9M | -$6.2M | -$6.7M |
| Income tax benefit | -$900.2K | -$136.7K | $0 |
| Net loss | -$5.0M | -$6.1M | -$6.7M |
| Net loss attributable to non-controlling interest | -$8.4K | -$6.0K | -$5.6K |
| Net loss attributable to Virax Biolabs shareholders | -$5.0M | -$6.1M | -$6.7M |
| Foreign currency adjustment | $422.6K | -$110.4K | -$3.6K |
| Total Comprehensive loss | -$5.5M | -$6.0M | -$6.7M |
| Comprehensive loss attributable to non-controlling interest | -$8.4K | -$6.0K | -$5.6K |
| Comprehensive loss attributable to Virax Biolabs shareholders | -$5.4M | -$6.0M | -$6.7M |
| Ordinary shares | 397.6K shares | 149.2K shares | 80.3K shares |
| Diluted ordinary shares | 397.6K shares | 149.2K shares | 80.3K shares |
| Basic net loss per share - Ordinary shares | -$12.64 | -$40.62 | -$83.90 |
| Diluted net loss per share - Ordinary shares | -$12.64 | -$40.62 | -$83.90 |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.8
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Cash | $6.4M | $4.2M | ||
| VAT receivable | $27.1K | $30.7K | ||
| Inventories | $0 | $94.7K | ||
| Prepaid expenses and deposits | $362.6K | $539.4K | ||
| Total current assets | $6.8M | $4.9M | ||
| Right-of-use assets, net | $327.4K | $306.7K | ||
| Property, plant & equipment, net | $1.2M | $1.2M | ||
| Total non-current assets | $1.5M | $1.5M | ||
| Total assets | $8.3M | $6.4M | ||
| Accounts payable and accrued liabilities | $309.5K | $250.2K | ||
| Lease liabilities, current | $81.1K | $53.0K | ||
| Accounts payable - related parties | $266.0K | $337.6K | ||
| Loan payable | $28.5K | $32.5K | ||
| Total current liabilities | $685.0K | $673.2K | ||
| Non-current lease liabilities | $304.8K | $291.5K | ||
| Total liabilities | $989.8K | $964.8K | ||
| Ordinary shares, $0.01 par value, 2,000,000 shares authorized; 579,218 and 173,679 issued and outstanding as of March 31, 2026 and 2025, respectively | $14.5K | $4.3K | ||
| Reserves | $37.5M | $30.2M | ||
| Accumulated deficit | -$29.6M | -$24.6M | ||
| Accumulated Other Comprehensive Income (loss) | -$310.3K | $112.3K | ||
| Total shareholders' equity (Virax Biolabs) | $7.6M | $5.7M | ||
| Non-controlling interests | -$242.4K | -$234.0K | ||
| Total shareholders' equity attributable to Virax Biolabs ordinary shareholders | $7.3M | $5.5M | $5.1M | $8.9M |
| Total liabilities and shareholders' equity | $8.3M | $6.4M | ||
| Par value | $0.03 | $0.03 | ||
| Number of shares authorised | 2.0M shares | 2.0M shares | ||
| Number of shares issued | 579.2K shares | 173.7K shares | ||
| Number of shares outstanding | 579.2K shares | 173.7K shares |
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Cash | $6.4M | $4.2M | ||
| VAT receivable | $27.1K | $30.7K | ||
| Inventories | $0 | $94.7K | ||
| Prepaid expenses and deposits | $362.6K | $539.4K | ||
| Total current assets | $6.8M | $4.9M | ||
| Right-of-use assets, net | $327.4K | $306.7K | ||
| Property, plant & equipment, net | $1.2M | $1.2M | ||
| Total non-current assets | $1.5M | $1.5M | ||
| Total assets | $8.3M | $6.4M | ||
| Accounts payable and accrued liabilities | $309.5K | $250.2K | ||
| Lease liabilities, current | $81.1K | $53.0K | ||
| Accounts payable - related parties | $266.0K | $337.6K | ||
| Loan payable | $28.5K | $32.5K | ||
| Total current liabilities | $685.0K | $673.2K | ||
| Non-current lease liabilities | $304.8K | $291.5K | ||
| Total liabilities | $989.8K | $964.8K | ||
| Ordinary shares, $0.01 par value, 2,000,000 shares authorized; 579,218 and 173,679 issued and outstanding as of March 31, 2026 and 2025, respectively | $14.5K | $4.3K | ||
| Reserves | $37.5M | $30.2M | ||
| Accumulated deficit | -$29.6M | -$24.6M | ||
| Accumulated Other Comprehensive Income (loss) | -$310.3K | $112.3K | ||
| Total shareholders' equity (Virax Biolabs) | $7.6M | $5.7M | ||
| Non-controlling interests | -$242.4K | -$234.0K | ||
| Total shareholders' equity attributable to Virax Biolabs ordinary shareholders | $7.3M | $5.5M | $5.1M | $8.9M |
| Total liabilities and shareholders' equity | $8.3M | $6.4M | ||
| Par value | $0.03 | $0.03 | ||
| Number of shares authorised | 2.0M shares | 2.0M shares | ||
| Number of shares issued | 579.2K shares | 173.7K shares | ||
| Number of shares outstanding | 579.2K shares | 173.7K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.8
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Net Loss | -$5.0M | -$6.1M | -$6.7M |
| Depreciation | $361.2K | $266.6K | $54.9K |
| Amortization of right-of-use assets | $77.8K | $76.8K | $48.2K |
| Impairment of intangible asset | $390.4K | ||
| Accretion expense | $51.9K | $45.6K | $30.0K |
| Stock-based compensation | $130.4K | $365.3K | $1.0M |
| Loss on disposal of property, plant & equipment | $32.2K | ||
| Gain on debt extinguishment | -$12.5K | ||
| Other expense | $85.5K | ||
| Foreign currency translation (gain) loss | -$501.9K | $123.7K | $3.7K |
| Prepaid expenses and deposits | $176.8K | -$26.6K | -$231.3K |
| VAT receivable | $3.5K | $187.2K | -$217.8K |
| Inventories | $94.7K | -$34.3K | -$60.4K |
| Loan payable | -$4.0K | $32.5K | -$149.9K |
| Accounts payable - related parties | -$71.6K | $337.6K | |
| Deferred revenue | -$38.2K | ||
| Accounts payable and accrued liabilities | $59.3K | $129.3K | -$572.2K |
| Net cash used in operating activities | -$4.6M | -$4.6M | -$6.4M |
| Investment - internally developed software | -$212.0K | ||
| Purchase of property, plant & equipment | -$255.8K | -$603.9K | -$952.5K |
| Net cash used in investing activities | -$255.8K | -$603.9K | -$1.2M |
| Lease payments | -$109.5K | -$107.8K | -$56.4K |
| Payments to related parties | -$18.3K | ||
| Proceeds from shares issuance for cash | $2.8M | $5.1M | $234 |
| Proceeds from PIPE transaction | $4.4M | ||
| Proceeds from warrant exercise | $705 | $786.7K | $1.9M |
| Net cash provided by financing activities | $7.1M | $5.8M | $1.8M |
| Net change in cash | $2.2M | $639.7K | -$5.8M |
| Interest | $41.0K | -$79.0K | $6.1K |
| Addition of Right-of-use assets | $80.9K | $181.6K | $254.3K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Virax Biolabs Group Ltd, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
- Chief executive officerJames Alexander Cunliffe Foster Mar 18, 2026 to now10
- Chief financial officerJason Davis Mar 18, 2026 to now11
- Chief operating officerNigel William McCracken Mar 20, 2026 to now12
Board members and other officers (2)
- Board memberIain David Miller Mar 18, 2026 to now13
- Board memberNigel William McCracken Mar 20, 2026 to now12
Named in SEC Form D filings
People the company listed in its private-offering notices.
- Executive Officer, DirectorMark Alexander Cunliffe Ternouth named Oct 17, 202314
- Executive Officer, DirectorCameron Alexander Cunliffe Shaw named Mar 15, 202315
- Executive OfficerMark Maurice Ternouth named Mar 15, 202315
- Executive OfficerTomasz Maurice George named Mar 15, 202315
- DirectorEvan Norton named Dec 18, 202516
- DirectorNelson Haight named Dec 18, 202516
- DirectorYair Erez named Dec 18, 202516
- DirectorEvan Alexander Cunliffe Norton named Mar 15, 2023 to Oct 17, 202314
- DirectorNelson Maurice Haight named Mar 15, 2023 to Oct 17, 202314
- DirectorYair Alexander Cunliffe Erez named Mar 15, 2023 to Oct 17, 202314
Former names
- Virax Biolabs (Cayman) LtdDec 27, 2021 to Dec 27, 20213
Timeline
Filings
157 filings to the SEC since October 2021: 5 annual reports, 6 insider forms, 8 large holders, 3 private raises, 135 other. The latest 20:
- Oct 9, 20266-K EDGAR
- Sep 10, 2026424B3 EDGAR
- Sep 4, 20266-K EDGAR
- Sep 4, 2026424B5 EDGAR
- Sep 3, 2026EFFECT EDGAR
- Sep 2, 2026F-3/A EDGAR
- Aug 26, 20266-K EDGAR
- Aug 18, 20266-K EDGAR
- Jul 31, 20266-K EDGAR
- Jul 24, 2026F-3 EDGAR
- Jul 16, 20266-K EDGAR
- Jul 10, 20266-K EDGAR
- Jul 9, 20266-K EDGAR
- Jul 6, 202620-F EDGAR
- Jun 24, 20266-K EDGAR
- Jun 12, 20266-K EDGAR
- May 26, 20266-K EDGAR
- May 22, 20266-K EDGAR
- May 15, 2026SCHEDULE 13G/A EDGAR
- Apr 14, 20266-K EDGAR
The 157 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 4 filings Feb 14, 2024 to May 15, 202617
- James Alexander Cunliffe FosterSCHEDULE 13G/A, 4 filings Oct 29, 202518
Money raised
Private offerings the company reported to the SEC on Form D.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARJason Davis, Chief financial officer
- 12
- 13SEC EDGARIain David Miller, Board member
- 14
- 15
- 16
- 17
- 18